{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:02:58Z","timestamp":1761843778113},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,7,11]],"date-time":"2008-07-11T00:00:00Z","timestamp":1215734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2008,7,11]],"date-time":"2008-07-11T00:00:00Z","timestamp":1215734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1007\/s10637-008-9154-z","type":"journal-article","created":{"date-parts":[[2008,7,10]],"date-time":"2008-07-10T05:49:11Z","timestamp":1215668951000},"page":"53-62","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy"],"prefix":"10.1007","volume":"27","author":[{"given":"Christopher","family":"Lieu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Scott","family":"Pierson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Gail","family":"Eckhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy L.","family":"O\u2019Bryant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zung Vu","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lia","family":"Gore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,7,11]]},"reference":[{"key":"9154_CR1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/1074-7613(95)90030-6","volume":"2","author":"MA Read","year":"1995","unstructured":"Read MA, Neish AS, Luscinskas FW et al (1995) The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 2:493\u2013506 doi:10.1016\/1074-7613(95)90030-6","journal-title":"Immunity"},{"key":"9154_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/00001813-200506000-00002","volume":"16","author":"I Zavrski","year":"1995","unstructured":"Zavrski I, Jakob C, Schmid P et al (1995) Proteasome: an emerging target for cancer therapy. Anticancer Drugs 16:475\u2013481 doi:10.1097\/00001813-200506000-00002","journal-title":"Anticancer Drugs"},{"key":"9154_CR3","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1126\/science.7725095","volume":"268","author":"AL Goldberg","year":"1995","unstructured":"Goldberg AL (1995) Functions of the proteasome: the lysis at the end of the tunnel. Science 268:522\u2013523 doi:10.1126\/science.7725095","journal-title":"Science"},{"key":"9154_CR4","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1309\/44HW-5YCJ-FLLP-3R56","volume":"116","author":"PJ Elliott","year":"2001","unstructured":"Elliott PJ, Ross JS (2001) The proteasome: a new target for novel drug therapies. Am J Clin Pathol 116:637\u2013646 doi:10.1309\/44HW-5YCJ-FLLP-3R56","journal-title":"Am J Clin Pathol"},{"key":"9154_CR5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1006\/bbrc.1995.2465","volume":"215","author":"CC Li","year":"1995","unstructured":"Li CC, Dai RM, Longo DL (1995) Inactivation of NF-kappa B inhibitor I kappa B alpha: ubiquitin-dependent proteolysis and its degradation product. Biochem Biophys Res Commun 215:292\u2013301 doi:10.1006\/bbrc.1995.2465","journal-title":"Biochem Biophys Res Commun"},{"key":"9154_CR6","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/00001622-200211000-00007","volume":"14","author":"J Adams","year":"2002","unstructured":"Adams J (2002) Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol 14:628\u2013634 doi:10.1097\/00001622-200211000-00007","journal-title":"Curr Opin Oncol"},{"key":"9154_CR7","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0093-7754(01)90034-X","volume":"28","author":"J Adams","year":"2001","unstructured":"Adams J (2001) Proteasome inhibition in cancer: development of PS-341. Semin Oncol 28:613\u2013619 doi:10.1016\/S0093-7754(01)90034-X","journal-title":"Semin Oncol"},{"key":"9154_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0960-894X(98)00029-8","volume":"8","author":"J Adams","year":"1998","unstructured":"Adams J, Behnke M, Chen S et al (1998) Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8:333\u2013338 doi:10.1016\/S0960-894X(98)00029-8","journal-title":"Bioorg Med Chem Lett"},{"key":"9154_CR9","first-page":"2638","volume":"5","author":"BA Teicher","year":"1999","unstructured":"Teicher BA, Ara G, Herbst R et al (1999) The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5:2638\u20132645","journal-title":"Clin Cancer Res"},{"key":"9154_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1634\/theoncologist.7-1-9","volume":"7","author":"J Adams","year":"2002","unstructured":"Adams J (2002) Development of the proteasome inhibitor PS-341. Oncologist 7:9\u201316 doi:10.1634\/theoncologist.7-1-9","journal-title":"Oncologist"},{"key":"9154_CR11","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1081\/CNV-120030223","volume":"22","author":"R Bold","year":"2004","unstructured":"Bold R (2004) Development of the proteasome inhibitor Velcade (bortezomib) in Adams J and Kauffman M. Cancer Invest 22:328\u2013329 doi:10.1081\/CNV-120030223","journal-title":"Cancer Invest"},{"key":"9154_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1006\/jsre.2001.6194","volume":"100","author":"RJ Bold","year":"2001","unstructured":"Bold RJ, Virudachalam S, McConkey DJ (2001) Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 100:11\u201317 doi:10.1006\/jsre.2001.6194","journal-title":"J Surg Res"},{"issue":"Suppl 1","key":"9154_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0305-7372(03)00079-3","volume":"29","author":"JC Cusack","year":"2003","unstructured":"Cusack JC (2003) Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 29(Suppl 1):21\u201331 doi:10.1016\/S0305-7372(03)00079-3","journal-title":"Cancer Treat Rev"},{"key":"9154_CR14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/jcb.1150","volume":"82","author":"SA Shah","year":"2001","unstructured":"Shah SA, Potter MW, McDade TP et al (2001) 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 82:110\u2013122 doi:10.1002\/jcb.1150","journal-title":"J Cell Biochem"},{"key":"9154_CR15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/sj.onc.1208225","volume":"24","author":"D Yin","year":"2005","unstructured":"Yin D, Zhou H, Kumagai T et al (2005) Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 24:344\u2013354 doi:10.1038\/sj.onc.1208225","journal-title":"Oncogene"},{"key":"9154_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1475-2867-5-18","volume":"5","author":"M Boccadoro","year":"2005","unstructured":"Boccadoro M, Morgan G, Cavenagh J (2005) Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 5:18 doi:10.1186\/1475-2867-5-18","journal-title":"Cancer Cell Int"},{"key":"9154_CR17","unstructured":"Millenium Pharmaceuticals (2004) Velcade (bortezomib) for injection. Investigator\u2019s brochure, March 18, 2004. Millenium Pharmaceuticals, Cambridge MA, USA"},{"key":"9154_CR18","first-page":"2505","volume":"8","author":"C Aghajanian","year":"2002","unstructured":"Aghajanian C, Soignet S, Dizon DS et al (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505\u20132511","journal-title":"Clin Cancer Res"},{"key":"9154_CR19","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1158\/1078-0432.CCR-04-2068","volume":"11","author":"GK Dy","year":"2005","unstructured":"Dy GK, Thomas JP, Wilding G et al (2005) A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, Velcade), in patients with advanced cancer. Clin Cancer Res 11:3410\u20133416 doi:10.1158\/1078-0432.CCR-04-2068","journal-title":"Clin Cancer Res"},{"key":"9154_CR20","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1200\/JCO.2004.02.106","volume":"22","author":"CN Papandreou","year":"2004","unstructured":"Papandreou CN, Daliani DD, Nix D et al (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108\u20132121 doi:10.1200\/JCO.2004.02.106","journal-title":"J Clin Oncol"},{"key":"9154_CR21","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1080\/07853890410029031","volume":"36","author":"DJ Park","year":"2004","unstructured":"Park DJ, Lenz HJ (2004) The role of proteasome inhibitors in solid tumors. Ann Med 36:296\u2013303 doi:10.1080\/07853890410029031","journal-title":"Ann Med"},{"key":"9154_CR22","first-page":"E61","volume":"92","author":"JP Spano","year":"2005","unstructured":"Spano JP, Bay JO, Blay JY, Rixe O (2005) Proteasome inhibition: a new approach for the treatment of malignancies. Bull Cancer 92:E61-66, 945\u2013952.","journal-title":"Bull Cancer"},{"key":"9154_CR23","unstructured":"Anonymous (2003) APEX (Assessment of Proteasome inhibition for extending remissions) trial: phase III randomized, multicenter, placebo-controlled trial to evaluate the efficacy and safety of bortezomib versus dexamethasone in patients with recurrent or treatment-resistant multiple myeloma. Clin Adv Hematol Oncol 1:190"},{"key":"9154_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1517\/14796694.1.2.161","volume":"1","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Mitsiades C (2005) Bortezomib: proteasome inhibition as an effective anticancer therapy. Future Oncol 1:161\u2013167 doi:10.1517\/14796694.1.2.161","journal-title":"Future Oncol"},{"key":"9154_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/JCO.2004.07.165","volume":"22","author":"NB Davis","year":"2004","unstructured":"Davis NB, Taber DA, Ansari RH et al (2004) Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol 22:115\u2013119 doi:10.1200\/JCO.2004.07.165","journal-title":"J Clin Oncol"},{"key":"9154_CR26","doi-asserted-by":"publisher","first-page":"6111","DOI":"10.1158\/1078-0432.CCR-04-0422","volume":"10","author":"MH Shah","year":"2004","unstructured":"Shah MH, Young D, Kindler HL et al (2004) Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 10:6111\u20136118 doi:10.1158\/1078-0432.CCR-04-0422","journal-title":"Clin Cancer Res"},{"key":"9154_CR27","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1002\/cncr.21108","volume":"103","author":"SN Markovic","year":"2005","unstructured":"Markovic SN, Geyer SM, Dawkins F et al (2005) A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 103:2584\u20132589 doi:10.1002\/cncr.21108","journal-title":"Cancer"},{"key":"9154_CR28","doi-asserted-by":"publisher","first-page":"5526","DOI":"10.1158\/1078-0432.CCR-05-0081","volume":"11","author":"H Mackay","year":"2005","unstructured":"Mackay H, Hedley D, Major P et al (2005) A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res 11:5526\u20135533 doi:10.1158\/1078-0432.CCR-05-0081","journal-title":"Clin Cancer Res"},{"key":"9154_CR29","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/cncr.20968","volume":"103","author":"RG Maki","year":"2005","unstructured":"Maki RG, Kraft AS, Scheu K et al (2005) A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 103:1431\u20131438 doi:10.1002\/cncr.20968","journal-title":"Cancer"},{"key":"9154_CR30","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1158\/1078-0432.CCR-05-1942","volume":"12","author":"WA Messersmith","year":"2006","unstructured":"Messersmith WA, Baker SD, Lassiter L et al (2006) Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 12:1270\u20131275 doi:10.1158\/1078-0432.CCR-05-1942","journal-title":"Clin Cancer Res"},{"key":"9154_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1146\/annurev.med.57.042905.122625","volume":"57","author":"PG Richardson","year":"2006","unstructured":"Richardson PG, Mitsiades C, Hideshima T, Anderson KC (2006) Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57:33\u201347 doi:10.1146\/annurev.med.57.042905.122625","journal-title":"Annu Rev Med"},{"key":"9154_CR32","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.2174\/0929867043364531","volume":"11","author":"P Meresse","year":"2004","unstructured":"Meresse P, Dechaux E, Monneret C, Bertounesque E (2004) Etoposide: discovery and medicinal chemistry. Curr Med Chem 11:2443\u20132466","journal-title":"Curr Med Chem"},{"key":"9154_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/0006-2952(91)90723-I","volume":"42","author":"G Los","year":"1991","unstructured":"Los G, Verdegaal E, Noteborn HP et al (1991) Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action. Biochem Pharmacol 42:357\u2013363 doi:10.1016\/0006-2952(91)90723-I","journal-title":"Biochem Pharmacol"},{"key":"9154_CR34","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/sj.bjc.6600540","volume":"87","author":"J Cosaert","year":"2002","unstructured":"Cosaert J, Quoix E (2002) Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer 87:825\u2013833 doi:10.1038\/sj.bjc.6600540","journal-title":"Br J Cancer"},{"key":"9154_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/0167-8140(88)90190-9","volume":"12","author":"J Glaholm","year":"1998","unstructured":"Glaholm J, Repetto L, Yarnold JR et al (1998) Carboplatin (JM8), etoposide (VP16) and thoracic irradiation for small cell lung cancer (S.C.L.C.): an evaluation of lung toxicity. Radiother Oncol 12:31\u201337 doi:10.1016\/0167-8140(88)90190-9","journal-title":"Radiother Oncol"},{"key":"9154_CR36","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1053\/suro.2002.37208","volume":"20","author":"CJ Ryan","year":"2002","unstructured":"Ryan CJ, Bajorin DF (2002) Chemotherapy for good-risk germ-cell tumors. Semin Urol Oncol 20:244\u2013250 doi:10.1053\/suro.2002.37208","journal-title":"Semin Urol Oncol"},{"key":"9154_CR37","first-page":"1087","volume":"4","author":"PA Bunn Jr","year":"1998","unstructured":"Bunn PA Jr, Kelly K (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4:1087\u20131100","journal-title":"Clin Cancer Res"},{"key":"9154_CR38","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0360-3016(01)01446-8","volume":"50","author":"SM Russo","year":"2001","unstructured":"Russo SM, Tepper JE, Baldwin AS Jr et al (2001) Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 50:183\u2013193 doi:10.1016\/S0360-3016(01)01446-8","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"9154_CR39","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","volume":"101","author":"N Mitsiades","year":"2003","unstructured":"Mitsiades N, Mitsiades CS, Richardson PG et al (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101:2377\u20132380 doi:10.1182\/blood-2002-06-1768","journal-title":"Blood"},{"key":"9154_CR40","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/ijc.21063","volume":"117","author":"T Fujita","year":"2005","unstructured":"Fujita T, Washio K, Takabatake D et al (2005) Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance. Int J Cancer 117:670\u2013682 doi:10.1002\/ijc.21063","journal-title":"Int J Cancer"},{"key":"9154_CR41","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748\u20131756","journal-title":"J Clin Oncol"},{"key":"9154_CR42","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1200\/JCO.1994.12.11.2471","volume":"12","author":"American Society of Clinical Oncology","year":"1994","unstructured":"American Society of Clinical Oncology (1994) Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 12:2471\u20132508","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-008-9154-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-008-9154-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-008-9154-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-008-9154-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:34:39Z","timestamp":1678559679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-008-9154-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,11]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["9154"],"URL":"https:\/\/doi.org\/10.1007\/s10637-008-9154-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,11]]},"assertion":[{"value":"21 March 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}